Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Cardlytics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Cardlytics şirketinin toplam hissedar öz sermayesi $210.0M ve toplam borcu $212.9M olup, bu da borç-öz sermaye oranını 101.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $534.4M ve $324.3M dir.

Anahtar bilgiler

101.4%

Borç/özkaynak oranı

US$212.89m

Borç

Faiz karşılama oranı	n/a
Nakit	US$71.25m
Eşitlik	US$210.03m
Toplam yükümlülükler	US$324.34m
Toplam varlıklar	US$534.37m

Son finansal sağlık güncellemeleri

Recent updates

Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)

Sep 17

Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk

Aug 09

Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain

Jul 02

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

May 31

The Power Of Cardlytics' Data Partnerships Including Bank of America

Apr 17

Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors

Apr 10

Cardlytics: Good Prospects But Macro Uncertain

Feb 16

Cardlytics, Inc.'s (NASDAQ:CDLX) 29% Share Price Plunge Could Signal Some Risk

Jan 18

Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?

Jan 04

We Think Cardlytics (NASDAQ:CDLX) Has A Fair Chunk Of Debt

Oct 05

Does Cardlytics (NASDAQ:CDLX) Have A Healthy Balance Sheet?

Jun 18

Cardlytics, Inc. (NASDAQ:CDLX) Stock Rockets 105% But Many Are Still Ignoring The Company

Apr 17

Is Cardlytics, Inc. (NASDAQ:CDLX) Trading At A 38% Discount?

Mar 03

Is Cardlytics (NASDAQ:CDLX) A Risky Investment?

Jan 10

Is Cardlytics (NASDAQ:CDLX) Using Debt In A Risky Way?

Oct 12

Cardlytics: 6 Bear Cases To Consider

Oct 10

Cardlytics: Trying To Stem The Bleeding

Sep 27

BitPay adds Cardlytics-powered rewards program to its crypto prepaid card

Aug 10

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CDLX 'nin kısa vadeli varlıkları ( $185.3M ) kısa vadeli yükümlülüklerini ( $104.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: CDLX 'un kısa vadeli varlıkları ( $185.3M ) uzun vadeli yükümlülüklerini ( $219.7M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CDLX 'nin net borç/öz sermaye oranı ( 67.4% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: CDLX şirketinin borç/öz sermaye oranı son 5 yılda 78.8% seviyesinden 101.4% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CDLX şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: CDLX, serbest nakit akışı her yıl % 13.7 oranında tarihi oranda azalmaya devam ederse 3 yıldan fazla bir süre yeterli nakit akışına sahip olur

Cardlytics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?

We Think Cardlytics (NASDAQ:CDLX) Has A Fair Chunk Of Debt

Does Cardlytics (NASDAQ:CDLX) Have A Healthy Balance Sheet?

Is Cardlytics (NASDAQ:CDLX) A Risky Investment?

Is Cardlytics (NASDAQ:CDLX) Using Debt In A Risky Way?

Recent updates

Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)

Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter 2024

Cardlytics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Consensus EPS estimates fall by 33%

Price target decreased by 21% to US$14.00

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Cardlytics, Inc. to Report Q1, 2024 Results on May 08, 2024

The Power Of Cardlytics' Data Partnerships Including Bank of America

Cardlytics, Inc., Annual General Meeting, May 23, 2024

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

CEO & Director notifies of intention to sell stock

Now 35% undervalued

Consensus estimates of losses per share improve by 18%

Cardlytics, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Cardlytics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 46% to US$17.00

New major risk - Share price stability

No longer forecast to breakeven

Cardlytics, Inc. Provides Earnings Guidance for the First Quarter of 2024

CEO & Director notifies of intention to sell stock

Cardlytics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Cardlytics: Good Prospects But Macro Uncertain

High number of new directors

COO & GM of Bridg exercised options and sold US$443k worth of stock

Cardlytics, Inc.'s (NASDAQ:CDLX) 29% Share Price Plunge Could Signal Some Risk

CEO & Director notifies of intention to sell stock

Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?

Kigo, LLC acquired HSP EPI Acquisition, LLC from Cardlytics, Inc. (NasdaqGM:CDLX).

CEO & Director exercised options and sold US$332k worth of stock

Consensus EPS estimates upgraded to US$1.32 loss, revenue downgraded

Cardlytics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardlytics, Inc. Announces Resignation of Tony Weisman as Member of the Board and as Member of the Nominating and Corporate Governance Committee

Cardlytics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

We Think Cardlytics (NASDAQ:CDLX) Has A Fair Chunk Of Debt

Cardlytics, Inc. Appoints Alex Mishurov as Independent Director

CEO & Director recently sold US$2.9m worth of stock

Cardlytics, Inc. Announces Board Member Changes

Insider recently sold US$172k worth of stock

Consensus EPS estimates fall by 29%, revenue upgraded

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Insufficient new directors

Cardlytics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Cardlytics Appoints Alexis Desieno as New Chief Financial Officer

Cardlytics, Inc. Announces Board Changes

Cardlytics, Inc. Announces Board Changes

CEO & Director notifies of intention to sell stock

Does Cardlytics (NASDAQ:CDLX) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$1.87 loss, revenue downgraded

Price target increased by 9.8% to US$6.70

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2023

Cardlytics, Inc. (NASDAQ:CDLX) Stock Rockets 105% But Many Are Still Ignoring The Company

Price target increased by 8.9% to US$6.10

Full year 2022 earnings: EPS misses analyst expectations

Is Cardlytics, Inc. (NASDAQ:CDLX) Trading At A 38% Discount?

Price target decreased by 18% to US$7.40

Cardlytics, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Cardlytics Appoints Amit Gupta as Chief Operating Officer

Is Cardlytics (NASDAQ:CDLX) A Risky Investment?

Cardlytics, Inc. Announces Board Changes